ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

JAK1

Janus kinase 1 · also JAK1A, JTK3, JAK1B · FERM domain containing

15 programs in company-led studies act on JAK1, from 12 companies: 9 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
upadacitinibruleAbbVieinhibitorphase 46424 runningJAK2, JAK3, TYK2ChEMBL
ruxolitinibruleIncyteinhibitorphase 49518 runningJAK2, JAK3, TYK2ChEMBL
baricitinibruleEli Lillyinhibitorphase 4598 runningJAK2NCIt
tofacitinibrulePfizerinhibitorphase 4943 runningJAK2, JAK3, TYK2ChEMBL
filgotinib maleateruleEisaiinhibitorphase 421 runningJAK2, JAK3, TYK2NCIt
jaktinibruleSuzhou Zelgen Biopharmaceuticalsinhibitorphase 3318 runningFLT3, JAK2, JAK3the studies' text
filgotinibruleLakefront Biotherapeutics NVinhibitorphase 3464 runningJAK2, JAK3, TYK2NCIt
ivarmacitinibruleJiangsu HengRui Medicineinhibitorphase 3254 running–NCIt
momelotinibruleGlaxoSmithKlineinhibitorphase 3174 runningACVR1, JAK2NCIt
abrocitinibrulePfizerinhibitorphase 3303 running–ChEMBL
FXS5626Fosun Pharma–phase 333 runningTYK2the company's pipeline
brepocitinibrulePfizerinhibitorphase 3252 runningTYK2NCIt
delgocitinibruleLEO Pharmainhibitorphase 3212 runningJAK2, JAK3, TYK2ChEMBL
golidocitinibruleDizal Pharmaceuticalsinhibitorphase 3102 running–NCIt
ABBV-7828AbbVie–phase 111 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.